Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
Gilead Sciences, Inc.
IndexS&P 500 P/E16.23 EPS (ttm)4.16 Insider Own0.40% Shs Outstand1.29B Perf Week0.18%
Market Cap87.19B Forward P/E9.69 EPS next Y6.98 Insider Trans-3.73% Shs Float1.28B Perf Month-0.07%
Income5.46B PEG- EPS next Q1.62 Inst Own81.40% Short Float1.05% Perf Quarter-4.70%
Sales22.13B P/S3.94 EPS this Y-22.80% Inst Trans0.01% Short Ratio1.63 Perf Half Y-9.69%
Book/sh17.64 P/B3.83 EPS next Y5.55% ROA3.30% Target Price84.49 Perf Year-17.39%
Cash/sh22.07 P/C3.06 EPS next 5Y-5.80% ROE10.30% 52W Range60.32 - 82.71 Perf YTD8.06%
Dividend2.52 P/FCF15.64 EPS past 5Y36.20% ROI19.90% 52W High-18.29% Beta1.23
Dividend %3.73% Quick Ratio3.40 Sales past 5Y21.90% Gross Margin78.10% 52W Low12.05% ATR1.55
Employees10000 Current Ratio3.50 Sales Q/Q-14.10% Oper. Margin47.60% RSI (14)50.28 Volatility1.72% 2.05%
OptionableYes Debt/Eq1.19 EPS Q/Q-22.10% Profit Margin10.00% Rel Volume0.75 Prev Close66.37
ShortableYes LT Debt/Eq1.07 EarningsFeb 04 AMC Payout128.20% Avg Volume8.23M Price67.59
Recom2.10 SMA20-0.99% SMA500.77% SMA200-5.00% Volume6,208,468 Change1.84%
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Feb-12-19Downgrade Citigroup Buy → Neutral $100 → $75
Jan-03-19Upgrade Oppenheimer Perform → Outperform $85
Oct-26-18Reiterated Barclays Overweight $90 → $95
Oct-26-18Downgrade Piper Jaffray Overweight → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $87
Jul-26-18Downgrade Robert W. Baird Outperform → Neutral $79
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Feb-15-19 04:40PM  U.S. Medicare plans to track CAR-T cancer therapy outcomes Reuters
04:09PM  Gilead Sciences, Inc. -- Moody's announces completion of a periodic review of ratings of Gilead Sciences, Inc. Moody's
02:16PM  Medicare would cover CAR-T therapies under new CMS proposal MarketWatch
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
01:00PM  Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings Zacks
10:08AM  Should You Buy Viking Therapeutics After Gilead Drug Failure? InvestorPlace
Feb-13-19 04:22PM  Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure Benzinga
03:34PM  Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars Zacks
11:40AM  Celgene vs. Gilead Stock: Whats the Better Biotech Buy? InvestorPlace
Feb-12-19 05:50PM  Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target American City Business Journals
04:24PM  Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib
04:20PM  Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails Zacks
04:15PM  Gilead Flops In Liver Disease Does Its Second Shot Have A Chance? Investor's Business Daily
03:55PM  5 Must-See Stock Charts for Wednesday: GILD, NFLX, EA InvestorPlace
02:57PM  Here's Why Viking Therapeutics Rose as Much as 13.9% Today Motley Fool
01:05PM  Gilead Sciences Stock Slides Lower on NASH Drug Failure InvestorPlace
12:12PM  Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech Benzinga
12:06PM  Gilead Sciences Stock Tumbles After Being Hit With Disappointing Trial Data
11:01AM  Viking Therapeutics Breaks Out After Gilead's Clinical Failure Investopedia
09:21AM  Gilead's Liver-Drug Setback Clouds  $35 Billion Dream Bloomberg
09:07AM  Gilead's Failed NASH Drug Trial Drags Stock Lower Benzinga
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
07:17AM  Better Buy: Gilead Sciences vs. Pfizer Motley Fool
03:06AM  Stocks - EA Jumps in Premarket; Walmart, Amazon Rise; Gilead, Aurora Slump
01:41AM  Stocks - U.S. Futures Jump as Congress Makes Border Wall Deal
Feb-11-19 06:00PM  Gilead misses key goal in NASH liver disease trial, shares sink Reuters
05:45PM  Gilead Slips After Liver Disease Treatment Fails In Late-Stage Test Investor's Business Daily
04:48PM  Gilead stock down nearly 4% as drug trial fizzles MarketWatch
04:30PM  Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) Business Wire
01:04PM  Stocks Moving After Hours: Bruker, Molina Health, Gilead, Activision
Feb-10-19 07:32PM  [$$] Big Pharmas Big Cancer Hope Is Fizzling The Wall Street Journal
12:00PM  Why Gilead Sciences Stock Perked Up in January Motley Fool
Feb-08-19 10:25AM  Why Agenus Inc. Stock Took Flight in January Motley Fool
Feb-07-19 03:03PM  For Sale: Performance Stocks, Slightly Worn Benzinga
09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 01:40PM  4 New CEOs to Watch in 2019 Investopedia
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
06:15AM  How Should You Value Gilead Sciences, Inc.s (NASDAQ:GILD)? Simply Wall St.
Feb-05-19 11:04PM  Edited Transcript of GILD earnings conference call or presentation 4-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
09:30PM  7 Key Things You Need to Know From Gilead Sciences' Q4 Earnings Update Motley Fool
05:02PM  Stock Market Today: Alphabet Grows While Gilead Sciences Shrinks Motley Fool
04:23PM  Gilead Sciences Drops Following Earnings Miss
03:49PM  5 Top Stock Trades for Wednesday: GOOGL, GILD, EL, BA InvestorPlace
03:26PM  Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4 Benzinga
01:14PM  Investor Movement Index January Summary Benzinga
12:35PM  2 Large-Cap Companies Report Earnings
11:22AM  Gilead Sciences Stock Is Sinking After Its Earnings Fell Short of Expectations
09:12AM  [$$] Stocks to Watch: Alphabet, Chevron, Gilead The Wall Street Journal
09:00AM  Gilead Stock Drops, Glu Sinks and 3 More Tuesday Morning Movers
08:53AM  UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day Zacks
08:43AM  Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
08:24AM  Is Gilead Sciences a Bad News Buy? Motley Fool
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
06:00AM  Gilead Sciences' HCV Albatross Weighs on Its Results Yet Again Motley Fool
03:10AM  Stocks - Alphabet, AMD, Gilead Slide in Premarket, Estée Lauder Soars
Feb-04-19 10:08PM  Gilead Sciences, Inc. (GILD) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:20PM  Gilead 4th-qtr profit misses Wall Street estimate, shares fall Reuters
05:59PM  Gilead Sciences Earnings: GILD Stock Dips on Q4 EPS Miss, Revenue Beat InvestorPlace
05:41PM  Alphabet (GOOGL) Outperforms Estimates, Gilead (GILD) Mixed Zacks
05:40PM  Gilead Sciences (GILD) Misses Q4 Earnings Estimates Zacks
05:16PM  Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings
05:11PM  Stocks making the biggest moves after hours: Alphabet, Gilead and more CNBC
04:48PM  Gilead Sciences reports quarterly earnings miss CNBC Videos
04:33PM  Gilead: 4Q Earnings Snapshot Associated Press
04:28PM  Gilead fourth-quarter profit misses Wall Street estimate, shares fall Reuters
04:19PM  Gilead Stock Topples On Mixed Fourth-Quarter Report As Earnings Miss Investor's Business Daily
04:17PM  Gilead stock falls after company's earnings miss MarketWatch
04:02PM  Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend Business Wire
04:01PM  Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results Business Wire
03:00PM  Gilead Sciences, Inc. to Host Earnings Call ACCESSWIRE
02:12PM  Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell
11:48AM  Midday Stock Market News: Alphabet, Gilead Earnings on Tap Motley Fool
11:24AM  Gilead Sciences Reports Earnings Today. Heres What to Expect.
07:45AM  What the Super Bowl Can Teach Us About Our Portfolio: Market Recon
07:32AM  Q4 Earnings Preview For Gilead Sciences Benzinga
01:42AM  Stocks - U.S. Futures Flat Amid Worry Over Slowing Chinese Economy
12:33AM  Top 5 Things to Know in The Market on Monday
Feb-03-19 12:59AM  Economic Calendar - Top 5 Things to Watch This Week
Jan-31-19 07:18PM  Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales? Zacks
09:53AM  4 Cash-Rich Stocks To Lead In A Debt-Laden Market Investopedia
08:25AM  3 Top Large-Cap Stocks to Buy in February Motley Fool
Jan-30-19 05:45PM  Gilead Sciences (GILD) Gains But Lags Market: What You Should Know Zacks
Jan-29-19 03:45PM  The Biggest Biotech Binary Event in 2019 Is Just Around the Corner Motley Fool
10:29AM  Avalon GloboCare Stock Is an Expensive Mystery InvestorPlace
Jan-28-19 03:47PM  Gilead Sciences Stock Could Have Plenty of Upside, Analyst Says
10:30AM  Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for Zacks
Jan-25-19 08:02PM  Four Low-Debt Stocks to Buy for Uncertain Times
05:30PM  New CEO completes round trip through Roche back to Genentech American City Business Journals
Jan-24-19 01:00PM  What's Behind the Biotech ETF Rally to Start 2019? Zacks
10:59AM  Healthcare ETFs in Focus Ahead of Q4 Earnings Zacks
08:30AM  Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead PR Newswire
08:00AM  Today's Research Reports on Trending Tickers: Celgene and Gilead Sciences ACCESSWIRE
Jan-23-19 05:50PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
05:05PM  3 Top Healthcare Stocks to Buy in January Motley Fool
08:16AM  3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss Motley Fool
Jan-22-19 04:05PM  Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019 Business Wire
Jan-19-19 12:00PM  Better Buy: Biogen vs. Gilead Sciences Motley Fool
Jan-18-19 04:12PM  These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts Investor's Business Daily
09:15AM  Searching For A Treatment: NASH Investigational Drugs With Catalysts This Year Benzinga
Jan-17-19 04:34PM  1 Chart That Shows Why Celgene Has Been Bought Out and Gilead Hasn't (Yet) Motley Fool
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for blood cancer; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it develops product candidates for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; TARGET PharmaSolutions, Inc.; Scholar Rock Holding Corporation; and Agenus Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorDec 03Option Exercise23.6050,0001,180,0002,927,762Dec 04 08:02 PM
MARTIN JOHN CDirectorDec 03Sale71.2050,0003,560,1782,877,762Dec 04 08:02 PM
MILLIGAN JOHN FPresident and CEONov 27Option Exercise23.60280,0006,608,0001,574,306Nov 29 08:42 PM
MARTIN JOHN CDirectorNov 01Option Exercise23.6050,0001,180,0003,067,762Nov 05 07:45 PM
MARTIN JOHN CDirectorNov 01Sale69.5550,0003,477,6173,017,762Nov 05 07:45 PM
MARTIN JOHN CDirectorOct 01Option Exercise23.6050,0001,180,0003,067,762Oct 03 05:45 PM
MARTIN JOHN CDirectorOct 01Sale78.0450,0003,902,2103,017,762Oct 03 05:45 PM
MARTIN JOHN CDirectorSep 04Option Exercise23.6050,0001,180,0003,067,762Sep 06 05:24 PM
MARTIN JOHN CDirectorSep 04Sale74.1650,0003,708,0343,017,762Sep 06 05:24 PM
MARTIN JOHN CDirectorAug 01Option Exercise23.6050,0001,180,0003,067,762Aug 03 04:41 PM
MARTIN JOHN CDirectorAug 01Sale77.8550,0003,892,6503,017,762Aug 03 04:41 PM
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM